Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Apr 3;13(2):325-328.
doi: 10.21037/hbsn-23-668. Epub 2024 Mar 29.

Improving patient stratification and selection for curative-intent treatment in localized pancreatic cancer

Mary P Martos #  1 , Haleh Amirian #  1 , Erin M Dickey  1 , Edmond W Box  1 , Nipun B Merchant  1   2 , Peter J Hosein  2   3 , Caitlin A Hester  1   2 , Jashodeep Datta  1   2
Affiliations
Editorial

Improving patient stratification and selection for curative-intent treatment in localized pancreatic cancer

Mary P Martos et al. Hepatobiliary Surg Nutr. .
No abstract available

Keywords: Pancreatic adenocarcinoma; pancreatic cancer; patient stratification; preoperative factors; prognostic model.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-23-668/coif). J.D. has a grant/contract from Cantargia AB that is unrelated to this work. The other authors have no conflicts of interest to declare.

Comment on

References

    1. Datta J, Merchant NB. Multimodality Therapy in Operable Pancreatic Cancer: Should We Sequence Surgery Last? Ann Surg Oncol 2021;28:1884-6. 10.1245/s10434-020-09400-x - DOI - PubMed
    1. Marcinak CT, Parker WF, Parikh AA, et al. Accuracy of models to prognosticate survival after surgery for pancreatic cancer in the era of neoadjuvant therapy. J Surg Oncol 2023;128:280-8. 10.1002/jso.27287 - DOI - PMC - PubMed
    1. Habib JR, Kinny-Köster B, Bou-Samra P, et al. Surgical Decision-Making in Pancreatic Ductal Adenocarcinoma: Modeling Prognosis Following Pancreatectomy in the Era of Induction and Neoadjuvant Chemotherapy. Ann Surg 2023;277:151-8. 10.1097/SLA.0000000000004915 - DOI - PubMed
    1. Janssen QP, van Dam JL, Bonsing BA, et al. Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial. BMC Cancer 2021;21:300. 10.1186/s12885-021-08031-z - DOI - PMC - PubMed
    1. Chawla A, Shi Q, Ko AH, et al. Alliance A021806: A phase III trial evaluating perioperative versus adjuvant therapy for resectable pancreatic cancer. J Clin Oncol 2023;41:TPS4204.